Jump to content

CD160

From Wikipedia, the free encyclopedia

CD160
Identifiers
AliasesCD160, BY55, NK1, NK28, CD160 molecule
External IDsOMIM: 604463; MGI: 1860383; HomoloGene: 5122; GeneCards: CD160; OMA:CD160 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_007053

NM_001163496
NM_001163497
NM_018767

RefSeq (protein)

NP_008984

NP_001156968
NP_001156969
NP_061237

Location (UCSC)Chr 1: 145.72 – 145.74 MbChr 3: 96.71 – 96.74 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

CD160 antigen is a protein that in humans is encoded by the CD160 gene.[5][6][7]

CD160 is a 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich, glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells, spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16+ cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab+CD8brightCD95+CD56+CD28-CD27-cells. In tissues, CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules.[7]

Clinical significance

[edit]

CD160 is a ligand for HVEM, and considered a proposed immune checkpoint inhibitor with anti-cancer activity along with anti- PD-1 antibodies.[8] CD160 has also been proposed as a potential new target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs.[9]

[edit]

See also

[edit]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000117281Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000038304Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Anumanthan A, Bensussan A, Boumsell L, Christ AD, Blumberg RS, Voss SD, et al. (September 1998). "Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes". Journal of Immunology. 161 (6): 2780–2790. doi:10.4049/jimmunol.161.6.2780. PMID 9743336. S2CID 25536877.
  6. ^ Agrawal S, Marquet J, Freeman GJ, Tawab A, Bouteiller PL, Roth P, et al. (February 1999). "Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells". Journal of Immunology. 162 (3): 1223–1226. doi:10.4049/jimmunol.162.3.1223. PMID 9973372. S2CID 23169904.
  7. ^ a b "Entrez Gene: CD160 CD160 molecule".
  8. ^ Stecher C, Battin C, Leitner J, Zettl M, Grabmeier-Pfistershammer K, Höller C, et al. (22 May 2017). "PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells". Frontiers in Immunology. 8: 572. doi:10.3389/fimmu.2017.00572. PMC 5439058. PMID 28588576.
  9. ^ Chabot S, Jabrane-Ferrat N, Bigot K, Tabiasco J, Provost A, Golzio M, et al. (May 2011). "A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor". The Journal of Experimental Medicine. 208 (5): 973–986. doi:10.1084/jem.20100810. PMC 3092350. PMID 21482699.
  10. ^ Klopocki E, Schulze H, Strauss G, Ott CE, Hall J, Trotier F, et al. (February 2007). "Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome". American Journal of Human Genetics. 80 (2): 232–240. doi:10.1086/510919. PMC 1785342. PMID 17236129.

Further reading

[edit]
[edit]